NCT03945175View on ClinicalTrials.gov

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions
Attention Deficit-Hyperactivity
Interventions
DRUG

MYDAYIS

MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.

DRUG

Placebo

During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.

Trial Locations (1)

10016

New York University School of Medicine, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03945175 - Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening | Biotech Hunter | Biotech Hunter